Multivalent Calixarene-Based Liposomes as Platforms for Gene and Drug Delivery.

dc.contributor.authorLebrón, José Antonio
dc.contributor.authorLópez-López, Manuel
dc.contributor.authorGarcía-Calderón, Clara B
dc.contributor.authorV Rosado, Ivan
dc.contributor.authorBalestra, Fernando R
dc.contributor.authorHuertas, Pablo
dc.contributor.authorRodik, Roman V
dc.contributor.authorKalchenko, Vitaly I
dc.contributor.authorBernal, Eva
dc.contributor.authorMoyá, María Luisa
dc.contributor.authorLópez-Cornejo, Pilar
dc.contributor.authorOstos, Francisco J
dc.date.accessioned2025-01-07T17:26:12Z
dc.date.available2025-01-07T17:26:12Z
dc.date.issued2021-08-12
dc.description.abstractThe formation of calixarene-based liposomes was investigated, and the characterization of these nanostructures was carried out using several techniques. Four amphiphilic calixarenes were used. The length of the hydrophobic chains attached to the lower rim as well as the nature of the polar group present in the upper rim of the calixarenes were varied. The lipid bilayer was formed with one calixarene and with the phospholipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, DOPE. The cytotoxicity of the liposomes for various cell lines was also studied. From the results obtained, the liposomes formed with the least cytotoxic calixarene, (TEAC12)4, were used as nanocarriers of both nucleic acids and the antineoplastic drug doxorubicin, DOX. Results showed that (TEAC12)4/DOPE/p-EGFP-C1 lipoplexes, of a given composition, can transfect the genetic material, although the transfection efficiency substantially increases in the presence of an additional amount of DOPE as coadjuvant. On the other hand, the (TEAC12)4/DOPE liposomes present a high doxorubicin encapsulation efficiency, and a slow controlled release, which could diminish the side effects of the drug.
dc.identifier.doi10.3390/pharmaceutics13081250
dc.identifier.issn1999-4923
dc.identifier.pmcPMC8398082
dc.identifier.pmid34452211
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8398082/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/1999-4923/13/8/1250/pdf?version=1629104853
dc.identifier.urihttps://hdl.handle.net/10668/28375
dc.issue.number8
dc.journal.titlePharmaceutics
dc.journal.titleabbreviationPharmaceutics
dc.language.isoen
dc.organizationCentro Andaluz de Biología Molecular (CABIMER)
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.organizationCentro Andaluz de Biología Molecular (CABIMER)
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectcationic calix[4]arenes
dc.subjectdoxorubicin
dc.subjectencapsulation
dc.subjectliposomes
dc.subjectnucleic acids
dc.subjecttransfection efficiency
dc.titleMultivalent Calixarene-Based Liposomes as Platforms for Gene and Drug Delivery.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number13

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8398082.pdf
Size:
7.74 MB
Format:
Adobe Portable Document Format